{
    "root": "e905b16a-58b6-4211-9931-dd2047db998a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Fluoxetine Hydrochloride",
    "value": "20250306",
    "ingredients": [
        {
            "name": "FLUOXETINE HYDROCHLORIDE",
            "code": "I9W7N6B1KJ"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "fluoxetine tablets indicated treatment : major depressive disorder ( mdd ) . efficacy fluoxetine mdd established one 5-week trial , three 6-week trials , one maintenance study adults . efficacy fluoxetine also established two 8- 9-week trials pediatric patients 8 18 years age [ ( 14.1 ) ] . obsessions compulsions patients obsessive compulsive disorder ( ocd ) . efficacy fluoxetine ocd demonstrated two 13-week trials adults one 13-week trial pediatric patients 7 17 years age [ ( 14.2 ) ] . binge-eating vomiting behaviors patients moderate severe bulimia nervosa . efficacy fluoxetine bulimia nervosa demonstrated two 8-week trials one 16-week trial adults [ ( 14.3 ) ] . panic disorder , without agoraphobia . efficacy fluoxetine panic disorder demonstrated two 12-week trials adults [ ( 14.4 ) ] .",
    "contraindications": "product available 60-mg form . 30-mg dose may achieved one-half scored tablet . product requires initial titration another fluoxetine product according dosing guidelines indicated .",
    "warningsAndPrecautions": "fluoxetine tablets usp , 60 mg , available 60-mg , white off-white film-coated , functional-scored , modified capsule shaped tablet , debossed `` l `` left score `` u `` right score one side tablet `` f57 `` left score plain right score side bottles 30 tablets ( ndc 68180-997-06 ) .",
    "adverseReactions": "monoamine oxidase inhibitors ( maois ) : maois intended treat psychiatric disorders fluoxetine within 5 weeks stopping treatment fluoxetine . fluoxetine within 14 days stopping maoi intended treat psychiatric disorders . addition , start fluoxetine patient treated linezolid intravenous methylene blue ( 4.1 , 7.1 ) pimozide ( 4.2 , 5.11 , 7.6 , 7.7 ) thioridazine : concomitantly within 5 weeks discontinuing fluoxetine ( 4.2 , 5.11 , 7.6 , 7.7 ) known hypersensitivity fluoxetine products ( 4.2 , 5.3 )",
    "indications_original": "Fluoxetine Tablets is indicated for the treatment of: \n                  \n                     Major Depressive Disorder (MDD). The efficacy of      fluoxetine in MDD was established in one 5-week trial, three 6-week      trials, and one maintenance study in adults. The efficacy of fluoxetine      was also established in two 8- to 9-week trials in pediatric patients 8 to      18 years of age [see CLINICAL STUDIES (14.1)]. \n                     \n                     Obsessions and compulsions in patients with Obsessive      Compulsive Disorder (OCD). The efficacy of fluoxetine in OCD was      demonstrated in two 13-week trials in adults and one\n                     13-week trial in pediatric patients 7 to 17 years of age [see CLINICAL STUDIES (14.2)]. \n                     \n                     Binge-eating and vomiting behaviors in patients with      moderate to severe Bulimia Nervosa.  The efficacy of fluoxetine in Bulimia      Nervosa was demonstrated in two 8-week trials      and one 16-week trial in adults [see CLINICAL STUDIES (14.3)]. \n                     \n                     Panic Disorder, with or      without agoraphobia. The efficacy of fluoxetine in Panic Disorder was      demonstrated in two 12-week trials in adults [see CLINICAL STUDIES (14.4)].",
    "contraindications_original": "This product is only available in a 60-mg dosage form. A 30-mg dose may be achieved with one-half of the scored tablet. Use of this product requires initial titration with another fluoxetine product according to the dosing guidelines indicated below.",
    "warningsAndPrecautions_original": "Fluoxetine tablets USP, 60 mg, are available as 60-mg, white to off-white film-coated, \n                        functional-scored, modified capsule shaped tablet, debossed with \"L\" on the left of the score and \"U\" on the right of the score on one side of the tablet and \"F57\" on the left of the score and plain on the right of the score on other side in bottles of 30 tablets (NDC 68180-997-06).",
    "adverseReactions_original": "Monoamine Oxidase Inhibitors (MAOIs): Do not use MAOIs intended to treat psychiatric disorders with fluoxetine or within 5 weeks of stopping treatment with fluoxetine.  Do not use fluoxetine within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start fluoxetine in a patient who is being treated with linezolid or intravenous methylene blue ( 4.1 , 7.1 ) Pimozide ( 4.2 , 5.11 , 7.6 , 7.7 ) Thioridazine: Do not use concomitantly with or within 5 weeks of discontinuing fluoxetine ( 4.2 , 5.11 , 7.6 , 7.7 ) Known hypersensitivity to fluoxetine products ( 4.2 , 5.3 )"
}